Zoll Medical's defibrillator gets US clearance:
This article was originally published in Clinica
Burlington, Massachusetts-based Zoll Medical has received US FDA 510(k) clearance for its Zoll M series defibrillator with end-tidal carbon dioxide (EtCO2) monitoring. The cardiac resuscitation device integrates a technology developed by Novametrix Medical Systems, called Capnostat, a solid-state sensor that monitors carbon dioxide and respiratory rate, pertinent to pacing and defibrillation. EtCO2 monitoring is the standard of care in hospital operating rooms, recovery areas, intensive care units and critical care units. The device can be used to assess patient airway integrity and proper endotracheal tube placement, the company said.